Murine cardiomyocytes ES

Cor.At^® cardiomyocytes are 100% pure, primary-like cardiomyocytes derived from mouse ES cells. Cor.At^® cardiomyocytes are reproducing an authentic cellular environment, which is fully characterized, including electrophyisology, gene analysis, and protein expression. Due to their unique properties, Cor.At^® cardiomyocytes can be used for various applications and experimental set-ups within the pharma industry as well as academia. Cor.At^® cardiomyocytes are available as GFP (Cor.At GFP) or non-GFP ("colorless", Cor.At CL) expressing cells in different formats.

Cor.At^® cardiomyocytes express all cardiac ion channels (Na⁺, Ca²⁺, K⁺), and can be used in electrophysiology studies to detect effects of compounds on ion channels (e.g. hERG blocker effects) as well as chronotropic and arrhythmic effects. All common patch clamp set-ups as well as automated systems (PatchXpress, Patchliner, QPatch) are supported to produce highly valuable and relevant data. Cor.At^® cardiomyocytes are also suitable for preclinical assessment of cardiac cytotoxicity and mitochondrial toxicity, and a predictive model for drug profiling and target discovery (e.g. hypertrophy studies, GPCR effects, siRNA, tissue engineering). Cor.At® cardiomyocytes are compatible with all common assay systems and instrumentation, including label-free detection systems.

Cor.At cardiomyocytes are 100% pure, primary-like cardiomyocytes as verified by GFP expression, morphology, immunostaining for cardiac-specific proteins, and gene analysis (Affymetrix Mouse Genome chip and RT-PCR). When seeded at sufficient density, Cor.At cardiomyocytes form a synchronously beating monolayer after approx. 24h of culture. Cor.At cardiomyocytes can be kept in culture for at least 3 weeks, allowing for long-term experiments. Over time, they will change their phenotype from early neonatal to adult, as in the developing mouse.

Cor.At cardiomyocytes are tested for their ability to react to known modulators of cardiac physiology, e.g. ion channel modulators or ß-adrenergic stimuli. The cells are validated for various applications using standard reference compounds with known in vivo activity. Please contact us for a comprehensive validation pack.

Cor.At GFP cardiomyocytes are 100% pure cardiomyocytes. They are delivered frozen in cryovials or 96 well plates. The proprietary technology ensures a stable and reproducible format with high lot-to-lot stability.

Cells are tested negative for mycoplasma and microbial contaminations. Guaranteed is a viability rate of at least 50 % measured by Trypan Blue exclusion. A Certificate of Analysis is included.

This product is for research purposes only. This product is not to be used for drug or diagnostic purposes, or for administration to humans. Products may not be resold, modified for resale, or used to manufacture commercial products without written approval of Lonza.

Viability is measured by Trypan blue exclusion assays and functional assays are performed on each lot to guarantee consistant performance of the cells.

Axiogenesis and Yamanaka (iPS Academia) sign

license agreement to generate

(iPS) derived HUMAN CARDIOMYOCYTES and other tissue

Important patent granted to Axiogenesis

in Europe and Japan

on the use of hypertrophic cardiac cells in drug development

Murine cardiomyocytes ES